Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Terminated 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Adenocarcinoma, Bronchiolo-Alveolar 1Adenocarcinoma of Lung 1

Interventions

Cisplatin 6Pemetrexed 5Carboplatin 5pembrolizumab 4Paclitaxel 4Magnetic Resonance Spectroscopy 4Docetaxel 4Gemcitabine 3Dexamethasone 3dexamethasone acetate 2dexamethasone 21-phosphate 2cemiplimab 2auricularum 2Specimen Handling 2Ramucirumab 2Radiotherapy 2Leucovorin 2Erlotinib Hydrochloride 2Drug Therapy 2Calcium Dobesilate 2pertuzumab 1oblimersen 1maimendongtang 1endostar protein 1cyclopropapyrroloindole 1cediranib 1aumolertinib 1anamorelin 1Vitamin B 12 1Vinorelbine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Lung Neoplasms × Pharmacogenomic Testing × Clear all
NCT01208064 2018-07-12

Pazopanib Hydrochloride or a Placebo in Treating Patients With Non-Small Cell Lung Cancer Who Have Received First-Line Chemotherapy

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2/3 Terminated
102 enrolled
Thoracic

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡